StockUS listing USIBRXNASDAQHealthcareProfitless Growth

Immunitybio Inc(IBRX) Stock Analysis | Healthcare

USD --+0.00%
Reward57Moderate
Risk35Moderate
75%Data
Revenue growing 94% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 10.90Bn
Reward Ratingⓘ57 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ35 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on IBRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Immunitybio Inc?

, a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.

AI Brief Pro

The brief on Immunitybio Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Immunitybio Inc?

, a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 10.90B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (57)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.135
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
7501,967 shares
$4.5M
0
9-12months
0
0